CompletedPHASE2, PHASE3NCT02942173

CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Principal Investigator
Michael Maschan, PhD, M.D
Fedaral Research Center for pediatric hematology, oncology and immunology
Intervention
CD45RA-depleted peripheral blood mononuclear cells(biological)
Enrollment
150 enrolled
Eligibility
25 years · All sexes
Timeline
20162020

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02942173 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials